Patents by Inventor Gabriel Rabinovich

Gabriel Rabinovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11723972
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 15, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Fundacion Sales
    Inventors: Margaret Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Publication number: 20200093920
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 26, 2020
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego O. Russo, Mariana Salatino
  • Patent number: 10456447
    Abstract: This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 29, 2019
    Assignee: Consejo Nacional de Investigacions Cientificas y Técnicas
    Inventors: Gabriel A. Rabinovich, Juan Pablo Cerliani, Nicolás Alejandro Pinto
  • Patent number: 10456465
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Publication number: 20190212330
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 11, 2019
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • Publication number: 20180110830
    Abstract: This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 26, 2018
    Inventors: Gabriel A. Rabinovich, Juan Pablo Cerliani, Nicolás Alejandro Pinto
  • Patent number: 9939428
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 10, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Publication number: 20160187340
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 30, 2016
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • Patent number: 9206427
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 8, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., CONICET, Fundacion Sales
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
  • Publication number: 20150191536
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 9, 2015
    Applicants: The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Patent number: 8968740
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 3, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Publication number: 20130011409
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 10, 2013
    Applicants: Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Dana-Farber-Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Publication number: 20090191182
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 30, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Quyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich
  • Publication number: 20090176223
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 9, 2009
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffrey Kutok, Scott Rodig, Gabriel Rabinovich